HC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price Target
Aardvark Therapeutics Inc AARD
$6.60
▲ +3.13%
(+$0.20)
⬆️ Above Yest. High
🗓️ Earnings Next Week
Open
$6.31
Prev Close
$6.40
Day Range
$5.62 – $6.66
52W Range
$3.35 – $17.94
Market Cap
$144.44M
Beta
3.76
EPS (TTM)
$-3.21
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2025-02-13 |
| Shares Out. | 21,880,000 |
| Website | aardvarktherapeutics.com/ ↗ |
| Phone | 18582257696 |
| Employees | 40 |
| Net Income | -$21.6M |
| Free Cash Flow | -$61.7M |
| Total Assets | $98.6M |
| Total Liabilities | $11.6M |
| Equity | $87.0M |
About Aardvark Therapeutics Inc
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Aardvark Therapeutics Inc is a publicly traded company under the ticker symbol AARD on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)